Rosana Meyer
YOU?
Author Swipe
View article: Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Tulmimetostat increases PRC2-repressed gene expression in ARID1A mutant bladder cancer cells. (
View article: Supplementary Figure S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Tulmimetostat demonstrates superior level of tumor PRC2 target gene inducon and correlation with efficacy in a bladder cancer xenograft mouse model.
View article: Supplementary Table S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
List of gene names corresponding to 132 tulmimetostat upregulated genes in responder versus non responder cell lines
View article: Data from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Data from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Recurrent somatic mutations in the BRG1/BRM-associated factor (BAF) chromatin remodeling complex subunit ARID1A occur frequently in advanced urothelial, endometrial, and ovarian clear cell carcinomas, creating an alternative chromatin stat…
View article: Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
In cancer patients tulmimetostat plasma exposure levels correlate with PRC2 target gene expression changes in peripheral blood.
View article: Supplementary Figure S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Tulmimetostat demonstrates superior level of tumor PRC2 target gene inducon and correlation with efficacy in a bladder cancer xenograft mouse model.
View article: Supplementary Figure S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Tulmimetostat improves cisplatin responsiveness in chemotherapy-resistant bladder cancer cells.
View article: Supplementary Table S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Table with cell line information including source and RRID
View article: Supplementary Table S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Table listing experimentally determined compound binding affinities for EZH2 and EZH1 containing PRC2 protein complexes
View article: Supplementary Figure S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Tulmimetostat mediated cancer cell phenotypic responses are increased in ARID1A LOF contexts.
View article: Supplementary Table S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
List of gene names corresponding to 132 tulmimetostat upregulated genes in responder versus non responder cell lines
View article: Supplementary Table S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Table with cell line information including source and RRID
View article: Supplementary Table S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Summary of cell viability data for bladder cancer cells treated with tulmimetostat
View article: Supplementary Materials and Methods from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Materials and Methods from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Additional method information to describe technical aspects of the experiments described in this manuscript
View article: Supplementary Table S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Table with antibody source information including RRID if available
View article: Supplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
List of 365 genes (used in main Fig. 7F) that are induced in patient’s whole blood upon treatment with tulmimetostat
View article: Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Tulmimetostat treatment results in greater PRC2 target gene expression induction in phenotypically sensitive ARID1A LOF cell lines
View article: Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
In cancer patients tulmimetostat plasma exposure levels correlate with PRC2 target gene expression changes in peripheral blood.
View article: Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Tulmimetostat treatment results in greater PRC2 target gene expression induction in phenotypically sensitive ARID1A LOF cell lines
View article: Supplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
List of 365 genes (used in main Fig. 7F) that are induced in patient’s whole blood upon treatment with tulmimetostat
View article: Supplementary Materials and Methods from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Materials and Methods from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Additional method information to describe technical aspects of the experiments described in this manuscript
View article: Supplementary Table S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Summary of PK data for EZH2 inhibitors used in KARPAS-422 and HT1376 xeograft mmouse models
View article: Supplementary Figure S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Synthetic pathway and characterization of tulmimetostat, a long residence time EZH2 inhibitor.
View article: Supplementary Table S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Table listing experimentally determined compound binding affinities for EZH2 and EZH1 containing PRC2 protein complexes
View article: Supplementary Table S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Summary of PK data for EZH2 inhibitors used in KARPAS-422 and HT1376 xeograft mmouse models
View article: Supplementary Figure S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Tulmimetostat mediated cancer cell phenotypic responses are increased in ARID1A LOF contexts.
View article: Supplementary Table S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Table with antibody source information including RRID if available
View article: Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Tulmimetostat increases PRC2-repressed gene expression in ARID1A mutant bladder cancer cells. (
View article: Supplementary Figure S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Figure S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Tulmimetostat improves cisplatin responsiveness in chemotherapy-resistant bladder cancer cells.
View article: Supplementary Table S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
Supplementary Table S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers Open
Summary of cell viability data for bladder cancer cells treated with tulmimetostat